Literature DB >> 17699471

Coronary artery disease.

Peter A McCullough1.   

Abstract

Coronary heart disease is the most common cause of death in the general population and in patients with ESRD. The principles of cardiovascular risk assessment and management apply to both populations. Advances in noninvasive coronary artery imaging have improved early detection of subclinical disease. The goals of medical management of coronary disease are to modify the natural history of disease and to improve the symptoms of angina. Coronary revascularization poses a different risk and benefit equation in the ESRD population. In stable ESRD with multivessel coronary artery disease, coronary bypass surgery, despite the upfront risks of stroke, myocardial infarction, and chest wound infection, seems to be a favored approach. In patients with ESRD and acute coronary syndromes, percutaneous coronary intervention on the target vessel has been associated with the most favorable outcomes. This article explores the clinical issues with respect to coronary artery disease in patients with ESRD.

Entities:  

Mesh:

Year:  2007        PMID: 17699471     DOI: 10.2215/CJN.03871106

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  24 in total

Review 1.  Cardiac imaging for the assessment of patients being evaluated for kidney or liver transplantation.

Authors:  Kalindi Parikh; Andrew Appis; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2014-10-08       Impact factor: 5.952

2.  Risk of Stroke in Patients with ESRD.

Authors:  Philip Masson; Patrick J Kelly; Jonathan C Craig; Richard I Lindley; Angela C Webster
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-24       Impact factor: 8.237

3.  Classifiers for Predicting Coronary Artery Disease Based on Gene Expression Profiles in Peripheral Blood Mononuclear Cells.

Authors:  Jie Liu; Xiaodong Wang; Junhua Lin; Shaohua Li; Guoxiong Deng; Jinru Wei
Journal:  Int J Gen Med       Date:  2021-09-15

4.  Metformin Attenuates Cardiac Hypertrophy Via the HIF-1α/PPAR-γ Signaling Pathway in High-Fat Diet Rats.

Authors:  Yuansheng Liu; Qian Zhang; Lei Yang; Wencong Tian; Yinan Yang; Yuhang Xie; Jing Li; Liang Yang; Yang Gao; Yang Xu; Jie Liu; Yachen Wang; Jie Yan; Guoxun Li; Yanna Shen; Zhi Qi
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

5.  Circular RNA circ_0001445 alleviates the ox-LDL-induced endothelial injury in human primary aortic endothelial cells through regulating ABCG1 via acting as a sponge of miR-208b-5p.

Authors:  Zhihua Yang; Xing Liang; Lixia Yang
Journal:  Gen Thorac Cardiovasc Surg       Date:  2022-04-07

6.  Comparison of Long-term Complications in Patients on Haemodialysis and Peritoneal Dialysis Longer than 10 Years.

Authors:  Arzu Ozdemir Kayalar; Taner Basturk; Yener Koc; Figen Yilmaz; Feyza Bayraktar Caglayan; Tamer Sakaci; Elbis Ahbap; Abdulkadir Ünsal
Journal:  J Clin Diagn Res       Date:  2016-02-01

7.  Cardiac troponins: outcome predictors in hemodialysis patients.

Authors:  Dejan Petrović; Biljana B Stojimirović
Journal:  J Artif Organs       Date:  2009-12-25       Impact factor: 1.731

8.  Gene-gene interactions among CX3CL1, LEPR and IL-6 related to coronary artery disease in Chinese Han population.

Authors:  Song-Gen Jin; Guo-Lin Chen; Song-Liu Yang; Ming-Yan Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

9.  Cardiovascular Outcomes in the Patients With Primary Central Nervous System Lymphoma: A Multi-Registry Based Cohort Study of 4,038 Cases.

Authors:  Zicong Qiu; Yongshi Tang; Yanting Jiang; Miao Su; Xuemin Wang; Xiuhong Xu; Yuerong Chen
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

10.  The P2Y 13 Met-158-Thr polymorphism, which is in linkage disequilibrium with the P2Y 12 locus, is not associated with acute myocardial infarction.

Authors:  Stefan Amisten; Oscar O Braun; Lovisa Johansson; Martin Ridderstråle; Olle Melander; David Erlinge
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.